+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07388524

Evaluating Atezolizumab Alone or with Hyaluronidase to Prevent Recurrence After Surgery in Stage I Non-Small Cell Lung Cancer A Phase III Randomized Trial

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

336

Participants Needed

133

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of atezolizumab, alone or combined with recombinant human hyaluronidase, compared to standard observation in preventing the return of stage I non-small cell lung cancer NSCLC after complete surgical removal. This phase III trial focuses on patients who have undergone surgical resection and aims to see if these immunotherapies may better prevent cancer recurrence than usual monitoring. Atezolizumab is a monoclonal antibody that may help the immune system attack cancer cells, and the combination with hyaluronidase may improve drug absorption. Participants are randomly assigned to one of two groups. One group undergoes observation with regular CT scans and optional blood sample collection for one year. The other group receives atezolizumab intravenously or atezolizumab with hyaluronidase subcutaneously every three weeks for up to one year 17 cycles, alongside similar monitoring. After treatment, patients are followed up at 30 days atezolizumab group only, then every 6 months for 3 years, and annually for an additional 7 years, totaling 10 years of follow-up. During the study, participants will have regular CT scans and may provide blood samples to help assess their health and disease status. Researchers will monitor disease-free survival, overall survival, recurrence rates, and adverse events over up to 10 years. Safety and treatment effects will be closely observed throughout treatment and follow-up to understand long-term outcomes and potential benefits of the therapies compared to observation alone.

CONDITIONS

Brief Title

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here